Filtered By:
Source: American Heart Journal
Condition: Heart Failure
Education: Study
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 73 results found since Jan 2013.
Scar tissue–guided left ventricular lead placement for cardiac resynchronization therapy in patients with ischemic cardiomyopathy: An acute pressure-volume loop study
Background: Response to cardiac resynchronization therapy (CRT) is hampered by the extent and location of left ventricular (LV) scar tissue. It is commonly advised to avoid scar tissue while placing the LV lead. However, whether individual patients benefit from this strategy remains unclear.Methods: Thirty-two CRT candidates with ischemic cardiomyopathy were enrolled from 2 successive clinical trials (TBS and E-pot study). Magnetic resonance imaging with late contrast enhancement was performed to assess location, degree and transmurality of LV scar tissue. Patients underwent invasive pressure-volume loop measurements to as...
Source: American Heart Journal - January 16, 2014 Category: Cardiology Authors: Gerben Jan de Roest, LiNa Wu, Carel C. de Cock, Matthijs L. Hendriks, Peter Paul H.M. Delnoy, Albert C. van Rossum, Cornelis P. Allaart Tags: Heart Failure Source Type: research
Growth differentiation factor 15 and cardiovascular events in patients with stable ischemic heart disease (The Heart and Soul Study)
Background: Growth differentiation factor 15 (GDF-15) is a relatively new biomarker that predicts mortality in patients with chronic stable angina or acute coronary syndrome. However, the association of GDF-15 with cardiovascular (CV) events and the mechanisms of this association are not well understood.Methods: We measured plasma GDF-15 and cardiac disease severity in 984 patients with stable ischemic heart disease who were recruited for the Heart and Soul Study between September 2000 and December 2002. Subsequent CV events (myocardial infarction, stroke, and CV death), hospitalization for heart failure, and all-cause mor...
Source: American Heart Journal - December 9, 2013 Category: Cardiology Authors: David W. Schopfer, Ivy A. Ku, Mathilda Regan, Mary A. Whooley Tags: Coronary Artery Disease Source Type: research
Burden, timing, and relationship of cardiovascular hospitalization to mortality among Medicare beneficiaries with newly diagnosed atrial fibrillation
Conclusions: Cardiovascular hospitalization is common in the first year after AF diagnosis. Atrial fibrillation, heart failure, myocardial infarction, and stroke/transient ischemic attack account for half of primary hospitalization diagnosis. Cardiovascular hospitalization is independently associated with mortality, irrespective of time from diagnosis to first hospitalization, and represents a critical inflection point in survival trajectory. These findings highlight the importance of CV hospitalization as a marker of disease progression and poor outcomes. Efforts to clarify the determinants of hospitalization could inform...
Source: American Heart Journal - August 12, 2013 Category: Cardiology Authors: Mintu P. Turakhia, Matthew D. Solomon, Mehul Jhaveri, Pamela Davis, Michael R. Eber, Ryan Conrad, Nicholas Summers, Darius Lakdawalla Tags: Electrophysiology Source Type: research
Evaluation of the dual peroxisome proliferator–activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trial
Conclusions: AleCardio will establish whether the PPAR-α/γ agonist aleglitazar improves cardiovascular outcomes in patients with diabetes and high-risk coronary disease.
Source: American Heart Journal - July 29, 2013 Category: Cardiology Authors: A. Michael Lincoff, Jean-Claude Tardif, Bruce Neal, Stephen J. Nicholls, Lars Rydén, Gregory G. Schwartz, Klas Malmberg, John B. Buse, Robert R. Henry, Hans Wedel, Arlette Weichert, Ruth Cannata, Diederick E. Grobbee Tags: Trial Design Source Type: research
Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: Results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial
Background: Patients with atrial fibrillation who are vitamin K antagonist (VKA)-naive may have a higher risk of thrombosis and/or bleeding than VKA-experienced patients.Methods and results: Using data from ARISTOTLE, we assessed baseline characteristics and the treatment effect of apixaban versus warfarin in the VKA-naive and VKA-experienced cohorts. We compared rates of study drug discontinuation and time-in-therapeutic range. Overall, 7,800 (43%) were VKA naive, and 10,401 were VKA experienced. At baseline, both groups were similar with respect to age and congestive heart failure, hypertension, age, diabetes, stroke sco...
Source: American Heart Journal - July 26, 2013 Category: Cardiology Authors: David A. Garcia, Lars Wallentin, Renato D. Lopes, Laine Thomas, John H. Alexander, Elaine M. Hylek, Jack Ansell, Michael Hanna, Fernando Lanas, Greg Flaker, Patrick Commerford, Denis Xavier, Dragos Vinereanu, Hongqiu Yang, Christopher B. Granger Tags: Electrophysiology Source Type: research
Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease
Background: The impact of nonpersistence on events and of events on persistence is unclear. We studied the effects of nonpersistence on outcomes and events on nonadherence in a randomized placebo controlled trial in 40 countries on 25,620 patients.Methods: In the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET), persistent patients (n = 20,991) were compared with individuals who had permanently stopped study medications (n = 4,629).Results: Older age, female gender, less physical activity, less education, and history of stroke/transient ischemic attack, depression, and diabetes we...
Source: American Heart Journal - June 26, 2013 Category: Cardiology Authors: Michael Böhm, Helmut Schumacher, Ulrich Laufs, Peter Sleight, Roland Schmieder, Thomas Unger, Koon Teo, Salim Yusuf Tags: Acute Ischemic Heart Disease Source Type: research
Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis
Background: Inflammation plays a fundamental role in atherothrombosis. Yet, whether direct inhibition of inflammation will reduce the occurrence of adverse cardiovascular outcomes is not known.Design: The Cardiovascular Inflammation Reduction Trial (CIRT) (ClinicalTrials.gov NCT01594333) will randomly allocate 7,000 patients with prior myocardial infarction (MI) and either type 2 diabetes or the metabolic syndrome to low-dose methotrexate (target dose 15-20 mg/wk) or placebo over an average follow-up period of 3 to 5 years. Low-dose methotrexate is a commonly used anti-inflammatory regimen for the treatment of rheumatoid a...
Source: American Heart Journal - May 6, 2013 Category: Cardiology Authors: Brendan M. Everett, Aruna D. Pradhan, Daniel H. Solomon, Nina Paynter, Jean MacFadyen, Elaine Zaharris, Milan Gupta, Michael Clearfield, Peter Libby, Ahmed A.K. Hasan, Robert J. Glynn, Paul M. Ridker Tags: Trial Design Source Type: research
Effect of atrioventricular and ventriculoventricular delay optimization on clinical and echocardiographic outcomes of patients treated with cardiac resynchronization therapy: A meta-analysis
Conclusion: The current literature suggests that routine AV and/or VV delay optimization has a neutral effect on clinical and echocardiographic outcomes based on pooled data from randomized and nonrandomized studies. Standardization of patient selection and optimization timing and method may help to further define the role of CRT device optimization.
Source: American Heart Journal - May 2, 2013 Category: Cardiology Authors: Dominique Auger, Ulas Hoke, Jeroen J. Bax, Eric Boersma, Victoria Delgado Tags: Curriculum in Cardiology Source Type: research
Ischemic stroke associated with left cardiac catheterization: The importance of modifiable and non-modifiable risk factors
Background: Stroke associated with left cardiac catheterization is a devastating complication, and its incidence has not changed over the decades.We investigated the incidence, in-hospital outcomes and the modifiable and non-modifiable risk factors for periprocedural ischemic stroke.Methods: Our retrospective cohort study included all patients experiencing periprocedural ischemic stroke among the 24,500 patients who underwent left cardiac catheterization between January 2003 and October 2010. The case group was compared with a group of control patients randomly selected among those who underwent the procedure during this p...
Source: American Heart Journal - January 21, 2013 Category: Cardiology Authors: Batric Popovic, Sylvain Carillo, Nelly Agrinier, Charles Christophe, Christine Selton-Suty, Yves Juillière, Etienne Aliot Tags: Interventional Cardiology Source Type: research
INtensive versus Standard Ambulatory Blood Pressure Lowering to Prevent Functional DeclINe In The ElderlY (INFINITY)
Reductions in mobility and cognitive function linked to accrual of brain microvascular disease related white matter hyperintensities (WMHs) on magnetic resonance imaging can occur in older hypertensive patients in as little as 2 years. We have designed a trial evaluating 2 levels of ambulatory blood pressure (ABP) control in individuals with normal or mildly impaired mobility and cognition who have detectable cerebrovascular disease (>0.5% WMH fraction of intracranial volume) on functional outcomes. The study is a prospective randomized, open-label trial with blinded end points, in patients ages ≥75 years with elevated 2...
Source: American Heart Journal - January 7, 2013 Category: Cardiology Authors: William B. White, Ravi Marfatia, Julia Schmidt, Dorothy B. Wakefield, Richard F. Kaplan, Richard W. Bohannon, Charles B. Hall, Charles R. Guttmann, Nicola Moscufo, Douglas Fellows, Leslie Wolfson Tags: Trial Design Source Type: research
